GILEAD SCIENCES SL

Gilead Sciences' lenacapavir, a biannual injection for PrEP, showed a 96% reduction in HIV infections in a study, prompting plans for regulatory approvals by 2024. The drug could transform HIV prevention, though concerns remain about global accessibility and cost.

Barclays analyst Carter Gould maintains Sell rating on Bristol-Myers Squibb (BMY) with a $43.00 price target, despite shares closing at $53.96. Gould, with a 52.88% success rate, covers Healthcare stocks like Eli Lilly & Co and Gilead Sciences. Bristol-Myers Squibb has a Hold consensus with a $49.55 price target, indicating an 8.17% downside. Morgan Stanley also maintains a Sell rating with a $37.00 target.

The U.S. completed an initial shipment of Marburg disease vaccines and therapeutic drugs to Rwanda, with plans for clinical trials. Rwanda detected its first outbreak in September, reporting 36 cases and 11 deaths. The Sabin Vaccine Institute delivered 700 doses for trials targeting frontline workers, and Gilead Sciences donated 5,000 vials of remdesivir for emergency use.

Gilead Sciences approves new license agreements for lenacapavir, an antiretroviral medication providing near-total protection from HIV infection, to be licensed in 120 countries.

Gilead Sciences' HIV prevention drug, Lenacapavir, will be available in 120 countries, excluding high-incidence nations like Brazil and Mexico. The drug, administered twice yearly, has shown high efficacy in clinical trials, but critics argue for broader access to combat the global HIV epidemic.

Experimental Marburg vaccines and therapeutics, including Gilead's remdesivir and Mapp's MBP-091, will soon arrive in Rwanda for clinical trials. Rwanda, facing its first Marburg outbreak with 41 cases, aims to start trials within days to protect healthcare workers. The Sabin Vaccine Institute is sending 700 doses of a single-dose vaccine, believed to be the furthest along in development.

The LLC model offers flexibility in deal structures, clear IP ownership, and efficient capital recycling, making it attractive for biotech companies like Nimbus Therapeutics. However, it may not suit all companies, particularly those with complex IP portfolios, and requires adaptable talent management.

Gilead to donate 5,000 vials of remdesivir to Rwanda for emergency use against Marburg Virus Disease outbreak, pending Rwanda FDA authorization. Remdesivir, not approved for MVD treatment globally, has broad-spectrum antiviral activity and was used in COVID-19 treatment.